Bcr-Abl is a tyrosine kinase that is known to play a major role in chronic myelogenous leukemia (CML), while Bruton’s tyrosine kinase (BTK) is implicated in B-cell malignancies (chronic lymphocytic leukemia and non-Hodgkin lymphomas). This evidence concerns the gene BTK and non-Hodgkin lymphoma.